http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jan 2025 06:05:35 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html <p>KeyBanc analyst Paul Knight highlighted WST, GXIG, and STVN as main beneficiaries following Abbott results and rising GLP-1 estimates.</p><p>The analyst commented: "We look at the demand posted by Abbott Laboratories (ABT) last Wednesday for Continuous Glucose Monitoring Devices, which showed 23% y/y growth and cited capacity constraints as the most recent indicator of demand for injection technology and overall Life Science Tools demand in 2025. Probably more impressive for the GLP-1 vendors is that market estimates for 2030, based on Evaluate Pharma data, have increased 48% in the last seven months to $153B. Sales in 2025 alone are expected to http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html Mon, 27 Jan 2025 06:05:35 -0400 ABT GXIG STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html <p>KeyBanc analyst Paul Knight highlighted WST, GXIG, and STVN as main beneficiaries following Abbott results and rising GLP-1 estimates.</p><p>The analyst commented: "We look at the demand posted by Abbott Laboratories (ABT) last Wednesday for Continuous Glucose Monitoring Devices, which showed 23% y/y growth and cited capacity constraints as the most recent indicator of demand for injection technology and overall Life Science Tools demand in 2025. Probably more impressive for the GLP-1 vendors is that market estimates for 2030, based on Evaluate Pharma data, have increased 48% in the last seven months to $153B. Sales in 2025 alone are expected to http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html Mon, 27 Jan 2025 06:05:35 -0400 ABT GXIG STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html <p>KeyBanc analyst Paul Knight highlighted WST, GXIG, and STVN as main beneficiaries following Abbott results and rising GLP-1 estimates.</p><p>The analyst commented: "We look at the demand posted by Abbott Laboratories (ABT) last Wednesday for Continuous Glucose Monitoring Devices, which showed 23% y/y growth and cited capacity constraints as the most recent indicator of demand for injection technology and overall Life Science Tools demand in 2025. Probably more impressive for the GLP-1 vendors is that market estimates for 2030, based on Evaluate Pharma data, have increased 48% in the last seven months to $153B. Sales in 2025 alone are expected to http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html Mon, 27 Jan 2025 06:05:35 -0400 ABT GXIG STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html <p>KeyBanc analyst Paul Knight highlighted WST, GXIG, and STVN as main beneficiaries following Abbott results and rising GLP-1 estimates.</p><p>The analyst commented: "We look at the demand posted by Abbott Laboratories (ABT) last Wednesday for Continuous Glucose Monitoring Devices, which showed 23% y/y growth and cited capacity constraints as the most recent indicator of demand for injection technology and overall Life Science Tools demand in 2025. Probably more impressive for the GLP-1 vendors is that market estimates for 2030, based on Evaluate Pharma data, have increased 48% in the last seven months to $153B. Sales in 2025 alone are expected to http://www.streetinsider.com/Analyst+Comments/KeyBanc+Highlights+WST%2C+GXIG%2C+and+STVN+as+GLP-1+Estimates+Raise/24248910.html Mon, 27 Jan 2025 06:05:35 -0400 ABT GXIG STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html <p>Keybanc analyst Paul Knight weighed in on Novo Nordisk's Phase 3 CagriSema results and their impact on the GLP-1 market.</p><p>The analyst said: "Friday, NVO presented Phase 3 results for its potentially new obesity treatment CagriSema. We don't view the potential of the GLP-1 market as significantly changed into 2030 for WST, GXIG, or STVN. Gerresheimer (GXIG) was cited as having significant dual chamber (CagriSema format) risk, and while the 2027 or later potential might be different, the Company has indicated potential GLP-1 sales of €300M-€350M are largely linked to existing therapeutics and orders. In addition, GXIG had slightly over €100M http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html Mon, 23 Dec 2024 05:30:44 -0400 GXIG LLY NVO STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html <p>Keybanc analyst Paul Knight weighed in on Novo Nordisk's Phase 3 CagriSema results and their impact on the GLP-1 market.</p><p>The analyst said: "Friday, NVO presented Phase 3 results for its potentially new obesity treatment CagriSema. We don't view the potential of the GLP-1 market as significantly changed into 2030 for WST, GXIG, or STVN. Gerresheimer (GXIG) was cited as having significant dual chamber (CagriSema format) risk, and while the 2027 or later potential might be different, the Company has indicated potential GLP-1 sales of €300M-€350M are largely linked to existing therapeutics and orders. In addition, GXIG had slightly over €100M http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html Mon, 23 Dec 2024 05:30:44 -0400 GXIG LLY NVO STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html <p>Keybanc analyst Paul Knight weighed in on Novo Nordisk's Phase 3 CagriSema results and their impact on the GLP-1 market.</p><p>The analyst said: "Friday, NVO presented Phase 3 results for its potentially new obesity treatment CagriSema. We don't view the potential of the GLP-1 market as significantly changed into 2030 for WST, GXIG, or STVN. Gerresheimer (GXIG) was cited as having significant dual chamber (CagriSema format) risk, and while the 2027 or later potential might be different, the Company has indicated potential GLP-1 sales of €300M-€350M are largely linked to existing therapeutics and orders. In addition, GXIG had slightly over €100M http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html Mon, 23 Dec 2024 05:30:44 -0400 GXIG LLY NVO STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html <p>Keybanc analyst Paul Knight weighed in on Novo Nordisk's Phase 3 CagriSema results and their impact on the GLP-1 market.</p><p>The analyst said: "Friday, NVO presented Phase 3 results for its potentially new obesity treatment CagriSema. We don't view the potential of the GLP-1 market as significantly changed into 2030 for WST, GXIG, or STVN. Gerresheimer (GXIG) was cited as having significant dual chamber (CagriSema format) risk, and while the 2027 or later potential might be different, the Company has indicated potential GLP-1 sales of €300M-€350M are largely linked to existing therapeutics and orders. In addition, GXIG had slightly over €100M http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html Mon, 23 Dec 2024 05:30:44 -0400 GXIG LLY NVO STVN WST http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html <p>Keybanc analyst Paul Knight weighed in on Novo Nordisk's Phase 3 CagriSema results and their impact on the GLP-1 market.</p><p>The analyst said: "Friday, NVO presented Phase 3 results for its potentially new obesity treatment CagriSema. We don't view the potential of the GLP-1 market as significantly changed into 2030 for WST, GXIG, or STVN. Gerresheimer (GXIG) was cited as having significant dual chamber (CagriSema format) risk, and while the 2027 or later potential might be different, the Company has indicated potential GLP-1 sales of €300M-€350M are largely linked to existing therapeutics and orders. In addition, GXIG had slightly over €100M http://www.streetinsider.com/Analyst+Comments/KeyBanc+Weighs+in+on+GLP-1+Injection+Leaders+Following+Latest+NVO+Results/24134939.html Mon, 23 Dec 2024 05:30:44 -0400 GXIG LLY NVO STVN WST